Sex: F
Vaccine: RAB
Symptoms: Inappropriate schedule of product administration, Viral titre
Clinical narrative: The patient messed up the days and received Rabavert vaccine on day 0 and day 6; Case reference number US-BN-2023-001696 is a spontaneous report initially received from a consumer (reference number: USBAV23-1765) on 20-Oct-2023 and concerns a female patient of unknown age.   The patient's medical history and concomitant medication details were not provided.   On an unspecified date, as also reported in May, the patient had complete post exposure series with Rabavert (batch number: unknown) at unknown dose, route and site of administration as post-exposure prophylaxis and as reported received their last shot in first week of June.   On an unspecified date, as reported few weeks ago and an unknown amount of time after completing post exposure series with Rabavert, the patient had a possible re-exposure.  On an unspecified date, as reported before receiving the booster doses of Rabavert, the patient had antibody titers 0.7.  On an unspecified date, an unknown amount of time after the re-exposure, also reported as day zero, the patient received first booster dose of Rabavert (batch number: unknown) at unknown dose, route and site of administered for post-exposure prophylaxis.  On an unspecified date, an unknown amount of time after the re-exposure, also reported as day six, the patient received second booster dose of Rabavert (batch number: unknown) at unknown dose, route and site of administration (explicitly coded as 'inappropriate schedule of vaccine administered').   On an unspecified date, also reported as nine days after the second shot, it was a low risk situation and would discuss with the physician about the possibility of exposure again, but the patient was aware that the vaccine would take a while for the antibodies to reach the peak. The patient asked if there was any information to revaccinate. The patient was not sure as it was stated that after a full series the neutralizing antibody titers would be high enough for at least six months, but was recommend to get booster for more than three months in case of an exposure. The patient was advised that it did not matter how many days have past, even if it was one day the patient need to get re-booster.  At the time of the initial report, it was unknown if the patient experienced any adverse event due to Rabavert vaccination.    Additional information received on 23-Oct-2023 included information about Rabavert vaccination and antibody titers level, updated patient's initials, updated reporter's address.  Additional information received on 23-Oct-2023 included local case ID.  Additional information received on 23-Oct-2023 included confirmation about patient's initials.; Reporter's Comments: A female patient of unknown age received second booster dose of Rabavert (unknown amount of time after the re-exposure, also reported as day six) at unknown dose, route and site of administration which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Rabavert vaccination. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A female patient of unknown age received second booster dose of Rabavert (unknown amount of time after the re-exposure, also reported as day six) at unknown dose, route and site of administration which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Rabavert vaccination. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.